Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) General Counsel Sells $52,308.24 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWNGet Free Report) General Counsel Adam Dubow sold 3,253 shares of Day One Biopharmaceuticals stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $16.08, for a total transaction of $52,308.24. Following the completion of the transaction, the general counsel now directly owns 21,731 shares in the company, valued at $349,434.48. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Day One Biopharmaceuticals Stock Performance

Shares of NASDAQ:DAWN opened at $16.17 on Friday. The company has a 50-day moving average price of $15.44 and a 200 day moving average price of $14.46. Day One Biopharmaceuticals, Inc. has a 52 week low of $9.67 and a 52 week high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWNGet Free Report) last posted its quarterly earnings results on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.07). On average, research analysts forecast that Day One Biopharmaceuticals, Inc. will post -2.83 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on DAWN. The Goldman Sachs Group lowered their price objective on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. Wedbush reissued an “outperform” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a report on Tuesday, May 7th. Oppenheimer reaffirmed a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. HC Wainwright lowered their target price on Day One Biopharmaceuticals from $50.00 to $40.00 and set a “buy” rating on the stock in a research note on Tuesday, May 7th. Finally, JPMorgan Chase & Co. boosted their target price on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a report on Monday, April 22nd. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Day One Biopharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $37.67.

View Our Latest Stock Analysis on Day One Biopharmaceuticals

Institutional Investors Weigh In On Day One Biopharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC lifted its stake in shares of Day One Biopharmaceuticals by 19.8% in the first quarter. Janus Henderson Group PLC now owns 2,032,384 shares of the company’s stock valued at $33,575,000 after purchasing an additional 336,281 shares during the period. Bayesian Capital Management LP acquired a new stake in shares of Day One Biopharmaceuticals during the 1st quarter valued at approximately $221,000. Estuary Capital Management LP boosted its stake in shares of Day One Biopharmaceuticals by 82.5% during the 1st quarter. Estuary Capital Management LP now owns 1,611,137 shares of the company’s stock worth $26,616,000 after acquiring an additional 728,240 shares in the last quarter. Altitude Crest Partners Inc. acquired a new stake in shares of Day One Biopharmaceuticals in the 1st quarter worth approximately $3,230,000. Finally, Summit Rock Advisors LP purchased a new position in Day One Biopharmaceuticals in the 1st quarter valued at approximately $851,000. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

Day One Biopharmaceuticals Company Profile

(Get Free Report)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.

See Also

Insider Buying and Selling by Quarter for Day One Biopharmaceuticals (NASDAQ:DAWN)

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.